TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
BerGenBio ASA ( (BRRGF) ) has provided an update.
Oncoinvent ASA has announced a fully underwritten rights issue to raise NOK 130 million, following the approval of a prospectus by the Financial Supervisory Authority of Norway. The rights issue involves the listing of new shares on the Oslo Stock Exchange, with subscription rights tradable under the ticker ‘ONCIT’. This financial move is expected to support the company’s operations and strengthen its market position, although existing shareholders may face dilution if they do not exercise their subscription rights.
The most recent analyst rating on (BRRGF) stock is a Buy with a NOK38.00 price target. To see the full list of analyst forecasts on BerGenBio ASA stock, see the BRRGF Stock Forecast page.
More about BerGenBio ASA
Oncoinvent is a clinical-stage biotechnology company focused on developing novel radiopharmaceutical therapies for cancer treatment. Its lead product, Radspherin®, targets micro-metastases in the peritoneum post-surgery using radium-224, offering a unique therapeutic approach with promising early clinical efficacy data. The company operates a state-of-the-art manufacturing facility in Oslo and is listed on the Oslo Stock Exchange.
YTD Price Performance: -88.17%
Average Trading Volume: 225,289
Current Market Cap: NOK258.3M
Find detailed analytics on BRRGF stock on TipRanks’ Stock Analysis page.